LAB — STANDARD BIOTOOLS INC.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1162194 ·
Last close
$0.74
Market Cap
$290.51M
52W High
$1.72
52W Low
$0.63
ADV30
1,554,590
Next earnings
2026-11-03

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 20,104,000 10,535,000 -7,829,000 -26,758,000 627,218,000 270,026,000 87,247,000
Mar 2026 21,146,000 11,308,000 -9,416,000 127,068,000 639,114,000 265,772,000 77,991,000
Dec 2025 23,795,000 11,382,000 -21,924,000 19,283,000 567,754,000 120,863,000 143,463,000
Sep 2025 19,552,000 9,484,000 -23,467,000 -34,687,000 539,636,000 129,418,000 139,977,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-80,300,000
Investing CF
$190,777,000
Financing CF
$330,000
CapEx
$-2,276,000
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$0.22
As of
2026-08-09

Balance + Analyst (yfinance extras)

Retained Earnings
$-1,160,237,000
Inventory
$17,103,000
Receivables
$15,747,000
ST Investments
$206,693,000
EBIT TTM
$-72,161,000
Pretax Income TTM
$-90,981,000
Interest Exp TTM
$26,000
Analysts
1

Yahoo Snapshot (yfinance, live)

Total Revenue
$84,597,000
EBITDA
$-53,072,000
Free Cash Flow
$176,583,248
Enterprise Value
$-177,752,624
Total Cash
$476,719,008
Total Debt
$28,087,000
Shares Out
392,578,808
Trailing EPS
$-0.13
Book Value
$1.38
ROE
-11.2%
ROA
-6.6%
Div Yield
—

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 85,331,000 -93,305,000 -74,896,000 567,754,000 143,463,000 424,291,000 -74,343,000
Dec 2024 91,008,000 -87,006,000 -138,885,000 612,345,000 140,623,000 471,722,000 -143,454,000
Dec 2023 106,340,000 -63,039,000 -74,656,000 323,067,000 471,118,000 -148,051,000 -43,287,000
Dec 2022 97,948,000 -102,616,000 -190,098,000 390,310,000 471,777,000 -81,467,000 -89,370,000

TTM Snapshot

Revenues TTM
$121,365,000
NetIncome TTM
$-109,017,000
OpCashFlow TTM
$0
Assets (Latest)
$390,310,000
Forward EPS
$-0.01

Max Pain — expiry 2026-11-20

max pain strike: $1.00 · spot: $0.74 · call oi: 1,499 · put oi: 619
Expected Move to 2026-11-20: ±$0.21 (28.49%) — implied range $0.53 – $0.95 · ATM straddle on $0.50 strike

Peers — same industry

TickerNameMarket CapLastDaily %
CATX Perspective Therapeutics, Inc. $287.66M $2.52 —
UPB Upstream Bio, Inc. $293.57M $5.36 —
FULC Fulcrum Therapeutics, Inc. $285.35M $3.74 —
RCKT ROCKET PHARMACEUTICALS, INC. $284.87M $2.60 —
ELTP ELITE PHARMACEUTICALS INC /NV/ $280.06M $0.26 —

News headlines (Yahoo Finance, 1h cache)

Standard BioTools Reports Second Quarter 2026 Financial Results
2026-08-05 20:05 · Yahoo
Standard BioTools Sells Mass Cytometry Business Amid Pending Merger With Treeline Biosciences
2026-07-28 14:26 · Yahoo
Standard BioTools Announces Sale of Mass Cytometry Business and Illumina’s Buyout of Contingent Payments to Advance Merger with Treeline Biosciences
2026-07-28 12:00 · Yahoo
Standard BioTools Announces Filing of Registration Statement in Connection with Treeline Biosciences Transaction
2026-07-20 11:30 · Yahoo
Standard BioTools and Treeline Biosciences Announce Merger Agreement
2026-06-08 11:30 · Yahoo
Standard BioTools Reports First Quarter 2026 Financial Results
2026-05-05 20:05 · Yahoo
Standard BioTools (LAB) Reports Q1 Loss, Tops Revenue Estimates
2026-05-06 00:30 · Yahoo
Standard BioTools (LAB) is One of the Best Life Sciences Penny Stocks, Here is Why
2026-04-14 05:29 · Yahoo
Standard BioTools to Announce First Quarter 2026 Financial Results on May 5, 2026
2026-04-21 11:00 · Yahoo
Labrador Gold to Host Investor Webinar on the Mariposa Gold Project in Yukon’s White Gold District
2026-06-11 11:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.